Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's average Total Assets Growth Rate was 10.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 8.20% per year.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Total Assets Related Terms
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Total Assets Chart
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Total Assets
1,448.79
1,355.22
1,430.33
2,053.16
2,339.78
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a Total Assets of HK$2,340 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Assets too high?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Total Assets is HK$2,340 Mil. Overall, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Assets compare to VRTX and REGN?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Assets of HK$2,340 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Total Assets is HK$2,340 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co stock overvalued right now?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a current Total Assets of HK$2,340 Mil. The current Total Assets is HK$2,340 Mil. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566), the current Total Assets is HK$2,340 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score
Get the complete analysis for HKSE:02566
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02566 has been successfully added to your 
